AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Inclusion Criteria: * Female aged 18-75 years old. * ECOG 0 or 1 point. * Advanced triple-negative invasive breast cancer : 1. The pathological classification is triple negative, specifically: 1. ER negative: IHC\<1%. 2. PR negative: IHC\<1%. 3. HER2 negative: IHC-/+ or IHC++ but FISH/CISH is negative. 2. Tumor staging: locally advanced or recurrent/metastatic breast cancer. * If the last chemotherapy drug in the previous adjuvant/neoadjuvant treatment stage is paclitaxel, paclitaxel liposome, paclitaxel albumin or docetaxel, it will take ≥6 months from the end of treatment to enrollment. * At least one objectively measurable lesion according to the RECIST 1.1 . * The main organs are functioning well, and the blood test results within 14 days before enrollment should meet the following requirements: 1. Routine blood test: 1. Hemoglobin (HB) ≥90 g/L. 2. Neutrophil count (ANC) ≥1.5×109/L. 3. Platelet count (PLT) ≥100×109/L. 2. Biochemical test: 1. Total bilirubin≤1.5×ULN (upper limit of normal). 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; if there is liver metastasis, ALT and AST ≤ 5×ULN. 3. Serum creatinine (Cr) ≤1.5 ULN or creatinine clearance ≥60mL/min. * Must not be regnant. * Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: * Pregnant, lactating or planning to become pregnant during the study period. * Allergic to any of the drugs in the study. * Previously received PD-1/PD-L1 antibody, CTLA-4 antibody, or anti-vascular targeted therapy. * Central nervous system (CNS) metastases. * Concomitant disease/medical history: 1. Patients with any known or suspected autoimmune diseases. 2. Hypertension. 3. Peripheral neuropathy ≥ Grade 2. 4. Persons with a history of unstable angina or arrhythmia. 5. Active or uncontrolled serious infection . 6. History of immunodeficiency. 7. Active hepatitis B or C. 8. interstitial lung disease or non-infectious pneumonia. 9. Active tuberculosis. 10. Urine protein is ≥++, and 24-hour urine protein quantitative is \>1.0g. 11. Suffered from other malignant tumors within 5 years before enrollment. 12. Unreduced toxicity . 13. Multiple factors that affect oral medications. 14. Abnormal coagulation function. 15. Major surgical treatment, open biopsy or traumatic injury within 4 weeks. 16. Tumor has invaded the periphery of important blood vessels. 17. Patients who have seizures. 18. Bleeding constitution or medical history. 19. Arterial/venous thrombotic events before enrollment or within 6 months. 20. Live attenuated vaccine vaccination within 28 days before the study. 21. Uncontrollable pleural, abdominal or pericardial effusion. 22. Other uncontrollable systemic diseases. * Other serious physical or mental diseases or laboratory abnormalities. * Patients who the researcher thinks are not suitable for this research. * Participated in clinical trials of other anti-tumor drugs within four weeks.